Johnson & Johnson Development Corporation (JJDC), the corporate venturing subsidiary of healthcare company Johnson & Johnson, and venture capital firm Atlas Venture have co-led a $12.9m series A round for pharmaeutical company Rodin Therapeutics.
US-based Rodin, a biotechnology company specialising in combating neurological disorders through epigenetics, will use the funds to develop its selective epigenetic modulators.
Bruce Booth, Rodin’s chairman and acting CEO, and also a partner at Atlas Venture, said: “Rodin has spent the last year validating the thesis that a unique chemistry approach, high potential biology, and a strong team [which] could drive generation of compelling therapies for central nervous system (CNS) diseases”
Biotechnology company Proteros, a founding shareholder in Rodin, has a strategic partnership with the Massachusetts-based outfit enabling Rodin to utilise Proteros’ structural biology platform and deep experience in CNS drug development.
JJDC and Atlas Venture also invested an undisclosed amount in Rodin’s seed funding round in June 2013.